

Indegene acquires Trilogy Writing & Consulting GmbH

28 March 2024 | News

To augment Indegene's depth of clinical and regulatory writing expertise



Bengaluru-based Indegene has announced the acquisition of Trilogy Writing & Consulting GmbH, a global provider of specialty medical writing capabilities across clinical, regulatory, safety and medical content to life sciences companies. The acquisition by Indegene Ireland, a subsidiary of Indegene Limited, augments Indegene's depth of clinical and regulatory writing expertise for market authorisation applications globally.

Trilogy Writing & Consulting is a Germany, UK, and US-based, medical writing consultancy with know-how in the development and delivery of clinical, regulatory, safety, and medical content. It applies its expertise and unique approaches to deliver quality medical writing output.

According to Grand View Research, the medical writing market was \$4.2 billion in 2023 and is forecasted to grow at 10.46% CAGR to \$8.4 billion by 2030. However, biopharma companies are increasingly challenged by a lack of internal expertise (especially in complex therapeutic areas), continuous pressure on margins, and stringent expectations from regulatory authorities.

By combining Trilogy's expertise in medical writing with Indegene's scalability and technology, especially Generative AI, life sciences companies stand to benefit by way of higher productivity, lower cost, and greater flexibility even as they set up themselves to be future-ready, ultimately leading to faster regulatory approval for their products.